Drug-Coated Balloons for Coronary Artery Disease

Jeger, Raban; Eccleshall, Simon; Ahmad, Wan Azman Wan; Ge, Junbo; Poerner, Tudor C.; Shin, Eun‐Seok; Alfonso, Fernándo; Latib, Azeem; Ong, Paul Jau Lueng; Rissanen, Tuomas T.; Saucedo, Jorge; Scheller, Bruno; Kleber, Franz X.

doi:10.1016/j.jcin.2020.02.043

Cited by 312 publications

(239 citation statements)

References 102 publications

Supporting

Mentioning

186

Contrasting

Order By: Relevance

“…More evidence supports the use of DCB in neonatal coronary artery disease. Raban et al [18] Selected 758 patients with de novo disease of coronary artery <3 mm and randomly divided them into DCB group ( n = 382) and DES group ( n = 376). The trial was conducted in 14 centers from 2012 to 2017.…”

Section: Discussmentioning

confidence: 99%

See 1 more Smart Citation

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

Hao

Huang

Wang

et al. 2021

J Cardiothorac Surg

View full text Add to dashboard Cite

background Drug-coated balloon (DCB) is a new technology that has emerged in recent years and has been proven to be effective and safe in the treatment of in-stent restenosis. The purpose of this article is to observe the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction. method We selected 80 patients admitted to the hospital for STEMI from January 2018 to December 2019. The subjects were randomly divided into a Yinyi (Liaoning) Biotech Bingo Drug Coated Balloon treatment group (balloon group, n = 38) and a drug-eluting stent (DES) treatment group (stent group, n = 42). Patients were followed up to understand the incidence of major adverse cardiovascular events (MACE) at 1 month, 6 months and 1 year after surgery. Coronary angiography was rechecked 1 year after surgery to understand the late lumen loss (LLL) in the two groups. result During the one-year follow-up, the LLL of the target lesion in the balloon group was -0.12±0.46 mm, while the target lesion in the stent group was 0.14±0.37 mm ( P <0.05). Within 1 year, the incidence of MACE in the balloon group was 11%, while the incidence of MACE in the stent group was 12%. There was no significant difference between the two groups. in conclusion When PCI is used for STEMI, only DCB therapy is safe and effective, and has shown good clinical effects during a one-year follow-up period.

show abstract

Section: Discussmentioning

confidence: 99%

“…First, DCB treatment can significantly shorten the application time of dual antiplatelet drugs, thereby reducing bleeding complications. According to the current consensus of experts, it is recommended to use dual antiplatelet therapy 1 month after DCB treatment [18]. However, it takes 6 months after the symptoms of DES stabilize [22].…”

Section: Discussmentioning

confidence: 99%

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

Hao

Huang

Wang

et al. 2021

J Cardiothorac Surg

View full text Add to dashboard Cite

show abstract

“…With regards to drug-coated balloon, evidence in large coronary arteries of 4 mm is limited though it has been successful in arteries with 3 mm diameter. 9 Moreover, it requires more aggressive lesion preparation with pre-dilatation having a balloon-to-vessel ratio of 0.8–1.0. 10 This increases the risk of dissection mandating stent implantation, the thing we were trying to avoid.…”

Section: Discussionmentioning

confidence: 99%

Management of acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura, the value of optical coherence tomography: a case report

Al-Lawati

Osheiba

Lester

et al. 2020

European Heart Journal - Case Reports

View full text Add to dashboard Cite

Background Treating myocardial infarction in the setting of immune thrombocytopenic purpura (ITP) is always a challenge especially if the platelet count is labile. Cardiologists dealing with such patients should keep a delicate balance between thrombotic and bleeding complications. Case summary A 50-year-old gentleman with treatment-challenging ITP presented with acute inferior ST elevation myocardial infarction after receiving recent intravenous immunoglobulin. Using optical coherence tomography (OCT) guidance, it was decided to treat him with percutaneous old balloon angioplasty especially with the labile nature of his platelet count. Subsequently, dual antiplatelet therapy was a challenge and he remained on clopidogrel for a period of only 10 weeks. Conclusion This case highlights the rare presentation of patients with ITP with thrombotic complications and the usefulness of OCT in formulating a management plan.

show abstract

“…Kissing balloon angioplasty is feasible in selected cases, although carina shift normally is caused by stent implantation and not by balloon angioplasty. 60 However, a DES MB and DCB SB strategy may be selected in case of a compromised result during the pre-dilation stage of DCB-only PCI.…”

Section: Bifurcation Lesionsmentioning

confidence: 99%

Clinical applications of drug-coated balloon: what have we learned and where are we going?

Dash¹,

Rohit²,

Ahmed³

et al. 2020

J Transcat Intervent

View full text Add to dashboard Cite

Since the introduction of coronary stents, in-stent restenosis has been one of the main stumbling blocks for its application in coronary artery disease. The drug-eluting stents have effectively reduced and become the mainstay of the interventional therapy of coronary artery disease. However, concerns of delayed stent thrombosis, dependency on prolonged dual antiplatelet therapy, and recurrent restenosis led to a quest for new treatment modalities that could address restenosis rates without drug-eluting-stent-related drawbacks. The drug-coated balloon has emerged as an additional tool in the armamentarium of interventional cardiology. It is usually a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima, leaving no implant behind. This review highlights the rationale for drug-coated balloon use, its effectiveness in different clinical and lesion settings, and the future perspective.

show abstract

Drug-Coated Balloons for Coronary Artery Disease

Cited by 312 publications

References 102 publications

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

Study on the safety and effectiveness of drug-coated balloons in patients with acute myocardial infarction

Management of acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura, the value of optical coherence tomography: a case report

Clinical applications of drug-coated balloon: what have we learned and where are we going?

Contact Info

Product

Resources

About